---
document_datetime: 2025-11-24 16:21:19
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sirturo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sirturo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2182791
conversion_datetime: 2025-12-27 09:13:11.867211
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## SIRTURO

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type II /  | C.I.6 Change(s) to therapeutic indication(s) - | 24/07/2025                          | 22/08/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion 'SIRTURO- |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000249065 C.I.6.a or Extension paediatric of age pulmonary Mycobacterium rifampicin the to is an to antimycobacterial bedaquiline multidrug-resistant-TB follow-up 1 (â‰¥12 to As and Leaflet the the the representatives introduce   | EMAVR0000249065'   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|